Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
45.28 USD | +1.29% | -7.46% | -11.75% |
05:50pm | Leerink Partners Cuts Price Target on Bristol-Myers Squibb to $47 From $51 | MT |
05:45pm | UBS Cuts Bristol-Myers Squibb Price Target to $47 From $52, Maintains Neutral Rating | MT |
Business Summary
The United States account for 70.1% of net sales.
Number of employees: 34,100
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Innovative Medicines
100.0
%
| 46,159 | 100.0 % | 45,006 | 100.0 % | -2.50% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
70.1
%
| 31,828 | 69.0 % | 31,555 | 70.1 % | -0.86% |
International
28.3
%
| 13,497 | 29.2 % | 12,752 | 28.3 % | -5.52% |
Other
1.6
%
| 834 | 1.8 % | 699 | 1.6 % | -16.19% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 53 | 15-01-31 | |
David Elkins
DFI | Director of Finance/CFO | 55 | 19-11-19 |
Greg Meyers
CTO | Chief Tech/Sci/R&D Officer | - | - |
Compliance Officer | - | 02-12-31 | |
Chief Tech/Sci/R&D Officer | - | - | |
Samit Hirawat
CTO | Chief Tech/Sci/R&D Officer | 55 | 18-12-31 |
Robert Plenge
CTO | Chief Tech/Sci/R&D Officer | 53 | 19-10-31 |
Laura Hortas
IRO | Public Communications Contact | - | - |
Corporate Officer/Principal | - | - | |
Cari Gallman
PRN | Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Phyllis Yale
BRD | Director/Board Member | 66 | 19-11-19 |
Peter Arduini
BRD | Director/Board Member | 59 | 16-03-31 |
Derica Rice
BRD | Director/Board Member | 59 | 20-08-31 |
Paula Price
BRD | Director/Board Member | 62 | 20-08-31 |
Theodore Samuels
BRD | Director/Board Member | 69 | 17-02-20 |
David Elkins
DFI | Director of Finance/CFO | 55 | 19-11-19 |
Chief Executive Officer | 53 | 15-01-31 | |
Julia Haller
BRD | Director/Board Member | 69 | 19-11-19 |
Deepak Bhatt
BRD | Director/Board Member | 56 | 22-06-13 |
Karen Vousden
BRD | Director/Board Member | 66 | 17-12-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 2,928,758,715 | 2,024,582,731 ( 69.13 %) | 902,000,000 ( 30.80 %) | 69.13 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
5,075,304 | 6.37% | 129,521,758 $ | |
KURA ONCOLOGY, INC. 1.80% | 1,370,171 | 1.80% | 29,225,747 $ |
UNIQURE N.V. 4.99% | 2,388,108 | 4.99% | 12,418,162 $ |
COMPUGEN LTD. 5.31% | 4,757,058 | 5.31% | 12,273,210 $ |
CELULARITY INC. 5.49% | 1,195,327 | 5.49% | 6,251,560 $ |
Company contact information
Bristol Myers Squibb Co.
Route 206 & Province Line Road
08543, Princeton
+609 252 4621
http://www.bms.comGroup companies
Name | Category and Sector |
---|---|
Bristol-Myers Squibb Pharmaceuticals Ltd.
Bristol-Myers Squibb Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Bristol-Myers Squibb Pharmaceuticals Ltd. manufactures pharmaceutical products. Its products are used for treatment of diseases like cancer, diabetes, arthritis, hepatitis, and psychiatric disorders. The company distributes products throughout the United Kingdom. Bristol-Myers Squibb Pharmaceuticals was founded in 1989 and is located in Uxbridge, UK. |
Pharmaceuticals: Major
|
Celgene Alpine Investment Co. LLC
| |
Bristol-Myers Squibb SARL
Bristol-Myers Squibb SARL Medical DistributorsDistribution Services Bristol-Myers Squibb SARL engages in the research, development, manufacture, and distribution of pharmaceutical products. Its therapeutic areas include immunoscience, immune-oncology, and cardiology. The company is headquartered in Rueil-Malmaison, France. |
Medical Distributors
|
Bristol-Myers Squibb Holdings Ireland Unlimited Co.
Bristol-Myers Squibb Holdings Ireland Unlimited Co. Pharmaceuticals: MajorHealth Technology Bristol-Myers Squibb Holdings Ireland Unlimited Co., a subsidiary of Bristol Myers Squibb Co., is a company headquartered in Ireland that operates as a holding company which develops medicines for serious diseases. |
Pharmaceuticals: Major
|
Bristol-Myers Squibb Australia Pty Ltd.
Bristol-Myers Squibb Australia Pty Ltd. Pharmaceuticals: MajorHealth Technology Bristol-Myers Squibb Australia Pty Ltd. is a biopharmaceutical company that researches, develops and markets medicines for serious diseases. The company was founded in 1930 and is headquartered in Noble Park North, Australia. |
Pharmaceuticals: Major
|
Bristol-Myers Squibb (Finland) Oy Ab
Bristol-Myers Squibb (Finland) Oy Ab Pharmaceuticals: GenericHealth Technology Part of Bristol Myers Squibb Co., Bristol-Myers Squibb (Finland) Oy Ab is a Finnish pharmaceutical manufacturing company. The private company is based in Vantaa, Finland. The company was founded in 1974. Simone Böhrer has been the CEO of the company since 2020. |
Pharmaceuticals: Generic
|
Bristol-Myers Squibb Belgium SA
Bristol-Myers Squibb Belgium SA Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Bristol-Myers Squibb Belgium SA develops, manufactures and distributes medicines. The private company is based in Watermael-Boitsfor, Belgium. The CEO of the Belgian company is Paul Lacante. |
Pharmaceuticals: Major
|
Bristol-Myers Squibb de México S de RL de CV
Bristol-Myers Squibb de México S de RL de CV Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Bristol-Myers Squibb de México S de RL de CV is a Mexican company that manufactures and supplies pharmaceutical and nutritional products. The private company is located in Mexico. |
Pharmaceuticals: Major
|
Bristol-Myers Squibb AB
Bristol-Myers Squibb AB Medical DistributorsDistribution Services Part of Bristol Myers Squibb Co., Bristol-Myers Squibb AB is a private company that wholesales medical equipment and pharmacy. The company is based in Solna, Sweden. |
Medical Distributors
|
Sector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.93% | 90.6B | |
+25.77% | 653B | |
+27.00% | 556B | |
-6.55% | 354B | |
+20.33% | 331B | |
+3.01% | 296B | |
+13.09% | 233B | |
+5.46% | 201B | |
-9.61% | 193B | |
-6.33% | 144B |
- Stock Market
- Equities
- BMY Stock
- Company Bristol-Myers Squibb Company